Putting the CARES trial under the microscope
The spotlight is on Takeda's urate-lowering drug febuxostat (Uloric) and its safety this Friday when a panel of FDA advisors convenes to discuss potential regulatory action regarding cardiovascular risk of this gout medicine. Febuxostat is currently indicated for the chronic management of hyperuricemia in patients with gout.